Nasdaq · CIK 0000886163
LGND LIGAND PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 6 d ago. Close $301.81 on Oct 9, 2026, +70% from the 52-week low and -6% from the high.
Last 90 days
Net insider value
-$3.3M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$3.3M by 2 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
LGNDOct 9, 2026 · close 301.81
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at LIGAND PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Andrew Reardon CLO & Secretary sell | $1.5M 5,000 shares | -14% | +70% from low-6% from high | |
| 43Moderate | Martine Zimmermann director sell | $342k 1,200 shares | -24% | - | |
| 33Weak | Andrew Reardon CLO & Secretary sell | $1.4M 5,000 shares | -12% | - | |
| 37Weak | Octavio Espinoza Chief Financial Officer sell | $340k 1,804 shares | -6% | +96% from low-9% from high | |
| 45Moderate | Nancy Ryan Gray director sell | $1.4M 6,571 shares | -56% | +109% from low-3% from high | |
| 45Moderate | Jason Aryeh director sell | $1.7M 10,000 shares | -13% | +77% from low-0% from high | |
| 3Weak | John W Kozarich director sell | $76k 467 shares | -1% | +69% from low0% from high | |
| 2Weak | John W Kozarich director sell | $62k 467 shares | -1% | +37% from low-6% from high | |
| 5Weak | John W Kozarich director sell | $117k 934 shares | -2% | +29% from low-4% from high | |
| 22Weak | Andrew Reardon CLO & Secretary sell | $57k 500 shares | -2% | +19% from low-11% from high | |
| 22Weak | Andrew Reardon CLO & Secretary sell | $57k 500 shares | -2% | +17% from low-13% from high | |
| 25Weak | Andrew Reardon CLO & Secretary sell | $104k 1,000 shares | -3% | +7% from low-20% from high | |
| 75Notable | Todd C Davis Chief Executive Officer buy | $1.0M 9,510 shares | +6% | +8% from low-20% from high | |
| 58Moderate | Octavio Espinoza Chief Financial Officer buy | $156k 1,500 shares | +6% | +8% from low-20% from high | |
| 46Moderate | Octavio Espinoza Chief Financial Officer sell | $575k 5,000 shares | -21% | - | |
| 35Weak | Octavio Espinoza Chief Financial Officer sell | $245k 2,104 shares | -9% | - | |
| 14Weak | John L Lamattina director sell | $298k 2,406 shares | -8% | - |
Congressional trades
4 trades in LGND disclosed by members of Congress under the STOCK Act. All congressional trades.
- Gilbert Ray Cisneros, Jr.House · D-CA · last Jun 8, 20264 bought
0 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | LGND Ligand Pharmaceuticals Incorporated - Common Stock | $1,001 to $15k | May 29 / Jun 8 10 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | LGND Ligand Pharmaceuticals Incorporated - Common Stock | $1,001 to $15k | Mar 3 / Apr 7 35 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | LGND Ligand Pharmaceuticals Incorporated - Common Stock | $1,001 to $15k | Jan 15 / Feb 13 29 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | LGND Ligand Pharmaceuticals Incorporated - Common Stock | $1,001 to $15k | Jan 5 / Feb 13 39 days after the trade | Clerk |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | MOption exercise Common Stock10b5-1 | +340 | $52.27 | $18k | 36,854 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -833 | $302.51 | $252k | 36,021 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -1,976 | $303.54 | $600k | 34,045 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -1,535 | $304.52 | $467k | 32,510 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -404 | $306.18 | $124k | 32,106 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -235 | $307.19 | $72k | 31,871 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -17 | $307.74 | $5,232 | 31,854 | 6 d ago |
| Oct 2, 2026 | Andrew Reardon CLO & Secretary | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -340 | $0.00 | $0 | 29,104 | 6 d ago |
| Sep 22, 2026 | Martine Zimmermann director | FTax withholding Common Stock | -115 | $298.50 | $34k | 3,782 | 18 d ago |
| Sep 10, 2026 | Martine Zimmermann director | SOpen-market sale Common Stock | -1,200 | $285.00 | $342k | 3,897 | 28 d ago |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -300 | $283.99 | $85k | 41,214 | 34 d ago |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -1,800 | $285.17 | $513k | 39,414 | 34 d ago |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -2,115 | $286.36 | $606k | 37,299 | 34 d ago |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -385 | $287.53 | $111k | 36,914 | 34 d ago |
| Sep 3, 2026 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock10b5-1 | -400 | $288.98 | $116k | 36,514 | 34 d ago |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Common Stock | +1,194 | $52.84 | $63k | 27,380 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Common Stock | +69 | $57.22 | $3,948 | 27,449 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Common Stock | +285 | $63.62 | $18k | 27,734 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Common Stock | +652 | $92.65 | $60k | 28,386 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Common Stock | +181 | $103.42 | $19k | 28,567 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -1,194 | $0.00 | $0 | 972 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -69 | $0.00 | $0 | 7,171 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -285 | $0.00 | $0 | 18,171 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -652 | $0.00 | $0 | 2,405 | Dec 18, 2025 |
| Dec 16, 2025 | Octavio Espinoza Chief Financial Officer | MOption exercise Employee Stock Option (right to buy)derivative | -181 | $0.00 | $0 | 4,186 | Dec 18, 2025 |
| Dec 12, 2025 | Octavio Espinoza Chief Financial Officer | SOpen-market sale Common Stock | -1,804 | $188.31 | $340k | 26,186 | Dec 16, 2025 |
| Dec 5, 2025 | Octavio Espinoza Chief Financial Officer | FTax withholding Common Stock | -1,862 | $184.87 | $344k | 27,990 | Dec 9, 2025 |
| Dec 8, 2025 | Jason Aryeh director | MOption exercise Common Stock | +2,034 | $69.51 | $141k | 71,323 | Dec 8, 2025 |
| Dec 4, 2025 | Todd C Davis Chief Executive Officer | GGift Common Stock | -130 | $0.00 | $0 | 161,337 | Dec 8, 2025 |
| Dec 8, 2025 | Jason Aryeh director | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -2,034 | $0.00 | $0 | 0 | Dec 8, 2025 |
| Nov 7, 2025 | Nancy Ryan Gray director | MOption exercise Common Stock | +3,556 | $66.19 | $235k | 11,650 | Nov 12, 2025 |
| Nov 7, 2025 | Nancy Ryan Gray director | SOpen-market sale Common Stock | -3,556 | $205.45 | $731k | 8,094 | Nov 12, 2025 |
| Nov 7, 2025 | Nancy Ryan Gray director | MOption exercise Common Stock | +3,015 | $73.57 | $222k | 11,109 | Nov 12, 2025 |
| Nov 7, 2025 | Nancy Ryan Gray director | SOpen-market sale Common Stock | -3,015 | $205.45 | $619k | 8,094 | Nov 12, 2025 |
| Nov 7, 2025 | Nancy Ryan Gray director | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -3,556 | $0.00 | $0 | 0 | Nov 12, 2025 |
| Nov 7, 2025 | Nancy Ryan Gray director | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -3,015 | $0.00 | $0 | 0 | Nov 12, 2025 |
| Sep 23, 2025 | Jason Aryeh director | SOpen-market sale Common Stock | -4,418 | $170.41 | $753k | 74,871 | Sep 24, 2025 |
| Sep 22, 2025 | Martine Zimmermann director | FTax withholding Common Stock | -115 | $170.77 | $20k | 4,443 | Sep 24, 2025 |
| Sep 23, 2025 | Jason Aryeh director | SOpen-market sale Common Stock | -4,628 | $170.96 | $791k | 70,243 | Sep 24, 2025 |
| Sep 23, 2025 | Jason Aryeh director | SOpen-market sale Common Stock | -954 | $171.92 | $164k | 69,289 | Sep 24, 2025 |
| Sep 2, 2025 | John W Kozarich director | SOpen-market sale Common Stock10b5-1 | -267 | $161.51 | $43k | 45,722 | Sep 4, 2025 |
| Sep 2, 2025 | John W Kozarich director | SOpen-market sale Common Stock10b5-1 | -115 | $162.52 | $19k | 45,607 | Sep 4, 2025 |
| Sep 2, 2025 | John W Kozarich director | SOpen-market sale Common Stock10b5-1 | -85 | $164.25 | $14k | 45,522 | Sep 4, 2025 |
| Aug 10, 2025 | Andrew Reardon CLO & Secretary | FTax withholding Common Stock | -1,325 | $150.06 | $199k | 30,811 | Aug 12, 2025 |
| Aug 1, 2025 | John W Kozarich director | SOpen-market sale Common Stock10b5-1 | -467 | $131.88 | $62k | 45,989 | Aug 5, 2025 |
| Jul 10, 2025 | John W Kozarich director | SOpen-market sale Common Stock10b5-1 | -934 | $125.00 | $117k | 46,456 | Jul 11, 2025 |
| Jun 30, 2025 | Todd C Davis Chief Executive Officer | JOther Common Stock | +233 | $91.08 | $21k | 161,467 | Jul 2, 2025 |
| Jun 30, 2025 | Octavio Espinoza Chief Financial Officer | JOther Common Stock | +224 | $91.08 | $20k | 29,852 | Jul 2, 2025 |
| Jun 30, 2025 | Andrew Reardon CLO & Secretary | JOther Common Stock | +233 | $91.08 | $21k | 32,136 | Jul 2, 2025 |
| Jun 23, 2025 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock | -500 | $114.08 | $57k | 31,903 | Jun 24, 2025 |
| Jun 10, 2025 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock | -500 | $114.54 | $57k | 32,403 | Jun 12, 2025 |
| Jun 6, 2025 | Martine Zimmermann director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 4,746 | Jun 10, 2025 |
| Jun 6, 2025 | Jason Aryeh director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 79,289 | Jun 10, 2025 |
| Jun 6, 2025 | Nancy Ryan Gray director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 8,094 | Jun 10, 2025 |
| Jun 6, 2025 | Jason Haas director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 6,606 | Jun 10, 2025 |
| Jun 6, 2025 | John W Kozarich director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 47,390 | Jun 10, 2025 |
| Jun 6, 2025 | John L Lamattina director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 30,724 | Jun 10, 2025 |
| Jun 6, 2025 | Stephen L Sabba director | AGrant or award Common Stock | +1,209 | $0.00 | $0 | 33,793 | Jun 10, 2025 |
| Jun 6, 2025 | Martine Zimmermann director | FTax withholding Common Stock | -188 | $105.99 | $20k | 4,558 | Jun 10, 2025 |
| Jun 6, 2025 | Nancy Ryan Gray director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jun 6, 2025 | Jason Haas director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jun 6, 2025 | John W Kozarich director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jun 6, 2025 | John L Lamattina director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jun 6, 2025 | Stephen L Sabba director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jun 6, 2025 | Martine Zimmermann director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jun 6, 2025 | Jason Aryeh director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +5,783 | $0.00 | $0 | 5,783 | Jun 10, 2025 |
| Jan 17, 2025 | John W Kozarich director | MOption exercise Common Stock | +2,406 | $52.30 | $126k | 46,181 | Jun 2, 2025 |
| Aug 10, 2024 | Andrew Reardon CLO & Secretary | FTax withholding Common Stock | -897 | $100.16 | $90k | 21,637 | Jun 2, 2025 |
| May 15, 2025 | Andrew Reardon CLO & Secretary | SOpen-market sale Common Stock | -1,000 | $104.00 | $104k | 32,903 | Jun 2, 2025 |
| Jan 17, 2025 | John W Kozarich director | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -2,406 | $0.00 | $0 | 0 | Jun 2, 2025 |
| May 9, 2025 | Todd C Davis Chief Executive Officer | POpen-market purchase Common Stock | +1,680 | $104.57 | $176k | 153,404 | May 13, 2025 |
| May 9, 2025 | Octavio Espinoza Chief Financial Officer | POpen-market purchase Common Stock | +1,000 | $103.89 | $104k | 27,432 | May 13, 2025 |
| May 9, 2025 | Todd C Davis Chief Executive Officer | POpen-market purchase Common Stock | +2,307 | $104.53 | $241k | 155,711 | May 13, 2025 |
| May 9, 2025 | Octavio Espinoza Chief Financial Officer | POpen-market purchase Common Stock | +500 | $104.40 | $52k | 27,932 | May 13, 2025 |
| May 9, 2025 | Todd C Davis Chief Executive Officer | POpen-market purchase Common Stock | +5,523 | $105.67 | $584k | 161,234 | May 13, 2025 |
| Apr 1, 2025 | Stephen L Sabba director | MOption exercise Common Stock | +2,406 | $52.30 | $126k | 32,584 | Apr 16, 2025 |
| Apr 1, 2025 | Stephen L Sabba director | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -2,406 | $0.00 | $0 | 0 | Apr 16, 2025 |
| Mar 4, 2025 | Todd C Davis Chief Executive Officer | AGrant or award Common Stock | +21,382 | $0.00 | $0 | 151,724 | Mar 6, 2025 |
| Mar 4, 2025 | Octavio Espinoza Chief Financial Officer | SOpen-market sale Common Stock | -5,000 | $115.03 | $575k | 18,879 | Mar 6, 2025 |
| Mar 4, 2025 | Andrew Reardon CLO & Secretary | AGrant or award Common Stock | +6,415 | $0.00 | $0 | 34,783 | Mar 6, 2025 |
| Mar 4, 2025 | Todd C Davis Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +93,476 | $0.00 | $0 | 93,476 | Mar 6, 2025 |
| Mar 4, 2025 | Octavio Espinoza Chief Financial Officer | AGrant or award Common Stock | +7,484 | $0.00 | $0 | 26,363 | Mar 6, 2025 |
| Mar 4, 2025 | Andrew Reardon CLO & Secretary | AGrant or award Employee Stock Option (right to buy)derivative | +28,043 | $0.00 | $0 | 28,043 | Mar 6, 2025 |
| Mar 4, 2025 | Octavio Espinoza Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +32,717 | $0.00 | $0 | 32,717 | Mar 6, 2025 |
| Feb 14, 2025 | Todd C Davis Chief Executive Officer | AGrant or award Common Stock | +20,784 | $0.00 | $0 | 143,794 | Feb 19, 2025 |
| Feb 14, 2025 | Octavio Espinoza Chief Financial Officer | AGrant or award Common Stock | +5,429 | $0.00 | $0 | 26,076 | Feb 19, 2025 |
| Feb 14, 2025 | Andrew Reardon CLO & Secretary | AGrant or award Common Stock | +6,928 | $0.00 | $0 | 29,462 | Feb 19, 2025 |
| Feb 14, 2025 | Todd C Davis Chief Executive Officer | FTax withholding Common Stock | -6,966 | $120.00 | $836k | 136,828 | Feb 19, 2025 |
| Feb 14, 2025 | Octavio Espinoza Chief Financial Officer | FTax withholding Common Stock | -2,757 | $120.00 | $331k | 23,319 | Feb 19, 2025 |
| Feb 14, 2025 | Andrew Reardon CLO & Secretary | FTax withholding Common Stock | -2,775 | $120.00 | $333k | 26,687 | Feb 19, 2025 |
| Feb 15, 2025 | Todd C Davis Chief Executive Officer | FTax withholding Common Stock | -2,231 | $120.00 | $268k | 134,597 | Feb 19, 2025 |
| Feb 14, 2025 | Octavio Espinoza Chief Financial Officer | AGrant or award Common Stock | +7,390 | $0.00 | $0 | 30,709 | Feb 19, 2025 |
| Feb 14, 2025 | Andrew Reardon CLO & Secretary | AGrant or award Common Stock | +5,429 | $0.00 | $0 | 32,116 | Feb 19, 2025 |
| Feb 15, 2025 | Todd C Davis Chief Executive Officer | FTax withholding Common Stock | -4,255 | $120.00 | $511k | 130,342 | Feb 19, 2025 |
| Feb 14, 2025 | Octavio Espinoza Chief Financial Officer | FTax withholding Common Stock | -3,803 | $120.00 | $456k | 26,906 | Feb 19, 2025 |
| Feb 14, 2025 | Andrew Reardon CLO & Secretary | FTax withholding Common Stock | -1,758 | $120.00 | $211k | 30,358 | Feb 19, 2025 |
| Feb 15, 2025 | Octavio Espinoza Chief Financial Officer | FTax withholding Common Stock | -1,024 | $120.00 | $123k | 25,882 | Feb 19, 2025 |
| Feb 15, 2025 | Andrew Reardon CLO & Secretary | FTax withholding Common Stock | -1,114 | $120.00 | $134k | 29,244 | Feb 19, 2025 |
| Feb 15, 2025 | Octavio Espinoza Chief Financial Officer | FTax withholding Common Stock | -782 | $120.00 | $94k | 25,100 | Feb 19, 2025 |
| Feb 15, 2025 | Andrew Reardon CLO & Secretary | FTax withholding Common Stock | -876 | $120.00 | $105k | 28,368 | Feb 19, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jason Aryehdirector
- Todd C DavisChief Executive Officer
- Octavio EspinozaChief Financial Officer
- Nancy Ryan Graydirector
- Jason Haascfo, officer, director
- John W Kozarichdirector
- John L Lamattinadirector
- Andrew ReardonCLO & Secretary
- Stephen L Sabbadirector
- Martine Zimmermanndirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.